Subscribe: Latest / All - Designed by Dr James P Howard (Google+)
ECASS II TRIAL |
|
|---|---|
| Problem | Acute ischaemic stroke |
| Format | - |
| Treatment | Alteplase |
| Control | Placebo |
| Population | 800 patients |
| Inclusion criteria | - |
| Exclusion criteria | - |
| Follow-up | 90 days |
| Primary endpoint | Modified Rankin scale (mRS) at 90 days, dichotomised for favourable (score 0-1) and unfavourable (score 2-6) outcome |
| Secondary endpoint(s) | . |
| Details | . |
| Brief summary: | |
| PAPER: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. | |
|---|---|
| Date | 17 Oct 1998 |
| Journal | Lancet. 1998 Oct 17;352(9136):1245-51. |
| Information | Alteplase within 6h of onset No significant benefit from alteplase -Trend towards efficacy |